Archive for September, 2010
Volatile Day for Mortgage Rates. Consumer Borrowing Costs Higher
Posted by: | CommentsPosted To: Mortgage Rate Watch
Mortgage rates opened just above record lows yesterday. Many lenders were seen offering mortgage rates below the 4.25% threshold. However as the day progressed, mortgage-backed securities (MBS) prices were pressured lower and lenders had to reprice for the worse, which pushed consumer closing costs higher by about 0.25% (of the loan amount) on the day. The economic data calendar was empty yesterday but we received several reports today. First out was the final revision to second quarter Gross Domestic Product. GDP is the broadest measure of total economic activity. It reports on the output of every economic sector. It’s basically our economic report card. A rapidly growing economy can lead to price inflation, one of the main enemies of low rates. The bond market prefers stable growth while…(read more)
Jeffries Gives New “Hold” Rating on Boston Scientific (NYSE: BSX)
Posted by: | CommentsEquities research analysts at Jeffries gave shares of Boston Scientific (NYSE: BSX) a new “hold” rating with a price target of $7.00 saying that it will take the company’s new management team time to grow outside of its areas of core competency.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties, including cardiac rhythm management, electrophysiology, interventional cardiology, peripheral interventions, neurovascular, endoscopy, urology, women’s health and neuromodulation. The Company’s products are offered for sale principally by six dedicated business groups: CRM, including its Cardiac Rhythm Management and Electrophysiology businesses; Cardiovascular, including its Interventional Cardiology and Peripheral Interventions businesses; Neurovascular; Endoscopy; Urology/Women’s Health, and Neuromodulation. During the year ended December 31, 2009, it derived 31% of its net sales from its CRM group, 43% from its Cardiovascular group, 12% from its Endoscopy business, 6% from its Urology/Women’s Health business, 4% from its Neuromodulation business, and 4% from its Neurovascular business.
Shares of BSX traded down 1.62% during mid-day trading on Wednesday.
This article (Jeffries Gives New “Hold” Rating on Boston Scientific (NYSE: BSX)) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.
Barclays PLC (NYSE: BCS) Boosts Estimates on Accenture (NYSE: ACN)
Posted by: | CommentsEquities research analysts at Barclays PLC (NYSE: BCS) raised their earnings per share estimates on shares of Accenture (NYSE: ACN) from $2.98 to $2.99 for 2011. Their 2010 earnings per share estimates remained flat at $2.62. The analysts reiterated an “overweight” rating and a $48.00 price target in a research note to investors on Wednesday.
Accenture plc is a management consulting, technology services and outsourcing company. The Company helps clients improve operational performance, deliver their products and services, increase revenues in markets and identify and enter new markets. Its business is organized in five operating groups: Communications & High Tech, Financial Services, Health & Public Service, Products and Resources. In October 2009, the Company acquired Symbian Professional Services from Nokia Corporation. In February 2010, the Company completed the acquisition of RiskControl, a consulting company based in Rio de Janeiro. In July 2010, the Company acquired Acceria.
Shares of ACN traded up 0.91% during mid-day trading on Wednesday.
This article (Barclays PLC (NYSE: BCS) Boosts Estimates on Accenture (NYSE: ACN)) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.